{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T13:43:49Z","timestamp":1793627029577,"version":"4.5.1"},"reference-count":99,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019519","name":"Kasturba Medical College, Manipal","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019519","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007075","name":"European Society for Medical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007075","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.annonc.2025.01.023","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T13:43:37Z","timestamp":1746711817000},"page":"626-644","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Peripheral T- and natural killer-cell lymphomas: ESMO\u2013EHA Clinical Practice Guideline for diagnosis, treatment and follow-up"],"prefix":"10.1016","volume":"36","author":[{"given":"F.","family":"d\u2019Amore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Federico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"de Leval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Ellin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Hermine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Lemonnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.S.P.","family":"Vermaat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Wulf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Buske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Dreyling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Jerkeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.annonc.2025.01.023_bib1","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.annonc.2025.01.023_bib2","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"suppl 4","key":"10.1016\/j.annonc.2025.01.023_bib3","doi-asserted-by":"crossref","first-page":"iv30","DOI":"10.1093\/annonc\/mdy133","article-title":"Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Willemze","year":"2018","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2025.01.023_bib4","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00428-023-03607-5","article-title":"Follicular helper T-cell lymphomas: disease spectrum, relationship with clonal hematopoiesis, and mimics. A report of the 2022 EA4HP\/SH lymphoma workshop","volume":"483","author":"Ondrejka","year":"2023","journal-title":"Virchows Arch"},{"issue":"3","key":"10.1016\/j.annonc.2025.01.023_bib5","doi-asserted-by":"crossref","first-page":"285","DOI":"10.6004\/jnccn.2022.0015","article-title":"T-cell lymphomas, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Horwitz","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"18","key":"10.1016\/j.annonc.2025.01.023_bib6","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1200\/JCO.2016.71.2083","article-title":"Impact of expert pathologic review of lymphoma diagnosis: study of patients from the French Lymphopath Network","volume":"35","author":"Laurent","year":"2017","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.annonc.2025.01.023_bib7","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1182\/blood.2022015520","article-title":"Lymph node excisions provide more precise lymphoma diagnoses than core biopsies: a French Lymphopath network survey","volume":"140","author":"Syrykh","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.annonc.2025.01.023_bib8","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/PAS.0000000000001991","article-title":"Core needle biopsy in lymphoma diagnosis: the diagnostic performance and the role of the multidisciplinary approach in the optimization of results","volume":"47","author":"Gon\u00e7alves","year":"2023","journal-title":"Am J Surg Pathol"},{"issue":"18","key":"10.1016\/j.annonc.2025.01.023_bib9","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/blood.2023021786","article-title":"A practical approach to the modern diagnosis and classification of T- and NK-cell lymphomas","volume":"144","author":"de Leval","year":"2024","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.annonc.2025.01.023_bib10","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/blood.2022015854","article-title":"Genomic profiling for clinical decision making in lymphoid neoplasms","volume":"140","author":"de Leval","year":"2022","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.annonc.2025.01.023_bib11","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1182\/blood.2019004118","article-title":"Hepatosplenic T-cell lymphoma: a rare but challenging entity","volume":"136","author":"Pro","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.annonc.2025.01.023_bib12","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/his.14093","article-title":"Challenges and limitations in the primary diagnosis of T-cell and natural killer cell\/T-cell lymphoma in bone marrow biopsy","volume":"77","author":"Attygalle","year":"2020","journal-title":"Histopathology"},{"issue":"2","key":"10.1016\/j.annonc.2025.01.023_bib13","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1182\/bloodadvances.2018024075","article-title":"Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma","volume":"3","author":"Mehta-Shah","year":"2019","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.annonc.2025.01.023_bib14","doi-asserted-by":"crossref","first-page":"e336","DOI":"10.1097\/RLU.0000000000002516","article-title":"Diagnostic and prognostic value of using 18F-FDG PET\/CT for the evaluation of bone marrow involvement in peripheral T-cell lymphoma","volume":"44","author":"Abe","year":"2019","journal-title":"Clin Nucl Med"},{"issue":"1","key":"10.1016\/j.annonc.2025.01.023_bib15","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/RLU.0000000000002320","article-title":"FDG PET for evaluation of bone marrow status in T-cell lymphoma","volume":"44","author":"Koh","year":"2019","journal-title":"Clin Nucl Med"},{"issue":"10","key":"10.1016\/j.annonc.2025.01.023_bib16","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.3324\/haematol.2019.225839","article-title":"Myeloproliferative and lymphoproliferative malignancies occurring in the same patient: a nationwide discovery cohort","volume":"105","author":"Holst","year":"2020","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.annonc.2025.01.023_bib17","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1182\/bloodadvances.2020001636","article-title":"Clonal hematopoiesis in angioimmunoblastic T-cell lymphoma with divergent evolution to myeloid neoplasms","volume":"4","author":"Lewis","year":"2020","journal-title":"Blood Adv"},{"issue":"18","key":"10.1016\/j.annonc.2025.01.023_bib18","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.annonc.2025.01.023_bib19","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"d'Amore","year":"2012","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2025.01.023_bib20","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/bjh.14740","article-title":"The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma: a Nordic Lymphoma Group study","volume":"178","author":"Cederleuf","year":"2017","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.annonc.2025.01.023_bib21","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.annonc.2025.01.023_bib22","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood.2021015114","article-title":"Impact of etoposide and ASCT on survival among patients aged <65 years with stage II to IV PTCL: a population-based cohort study","volume":"140","author":"Brink","year":"2022","journal-title":"Blood"},{"issue":"10168","key":"10.1016\/j.annonc.2025.01.023_bib23","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.annonc.2025.01.023_bib24","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/bjh.13855","article-title":"A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial","volume":"172","author":"Advani","year":"2016","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.annonc.2025.01.023_bib25","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41375-020-0838-5","article-title":"Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B\/ACT-2 trial","volume":"35","author":"Wulf","year":"2021","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.annonc.2025.01.023_bib26","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.21.01815","article-title":"Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the Ro-CHOP phase III study (Conducted by LYSA)","volume":"40","author":"Bachy","year":"2022","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.annonc.2025.01.023_bib27","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1200\/JCO.23.01687","article-title":"Romidepsin plus cyclophosphamide, doxorubicin, vincristine, and prednisone versus cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated peripheral T-cell lymphoma: final analysis of the Ro-CHOP trial","volume":"42","author":"Camus","year":"2024","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.annonc.2025.01.023_bib28","first-page":"2194","article-title":"Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL","volume":"141","author":"Ruan","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.annonc.2025.01.023_bib29","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","article-title":"Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study","volume":"27","author":"Reimer","year":"2009","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2025.01.023_bib30","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.3324\/haematol.2021.279426","article-title":"Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO\/FIL study","volume":"107","author":"Garc\u00eda-Sancho","year":"2022","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.annonc.2025.01.023_bib31","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41408-023-00868-w","article-title":"Real-world data of long-term survival in patients with T-cell lymphoma who underwent stem cell transplantation","volume":"13","author":"Baek","year":"2023","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.annonc.2025.01.023_bib32","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/annonc\/mdx787","article-title":"Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers","volume":"29","author":"Fossard","year":"2018","journal-title":"Ann Oncol"},{"issue":"19","key":"10.1016\/j.annonc.2025.01.023_bib33","first-page":"2646","article-title":"A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL","volume":"137","author":"Schmitz","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.annonc.2025.01.023_bib34","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/ajh.26803","article-title":"Outcome of limited-stage peripheral T-Cell lymphoma after CHOP(-like) therapy: a population based study of 239 patients from the Nordic lymphoma epidemiology group","volume":"98","author":"Ludvigsen Al-Mashhadi","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.annonc.2025.01.023_bib35","article-title":"Chemotherapy plus radiotherapy versus chemotherapy alone for patients with peripheral T-cell lymphoma, not otherwise specified","volume":"11","author":"Chen","year":"2021","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2025.01.023_bib36","first-page":"1163","article-title":"Outcome of combined modality treatment in first-line for stage I(E) peripheral T-cell lymphoma; a nationwide population-based cohort study from the Netherlands","volume":"109","author":"Meeuwes","year":"2024","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.annonc.2025.01.023_bib37","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/ejh.12060","article-title":"Favorable outcome with doxorubicin-based chemotherapy and radiotherapy for adult patients with early stage primary systemic anaplastic large-cell lymphoma","volume":"90","author":"Zhang","year":"2013","journal-title":"Eur J Haematol"},{"issue":"3","key":"10.1016\/j.annonc.2025.01.023_bib38","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","article-title":"The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma","volume":"33","author":"Horwitz","year":"2022","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2025.01.023_bib39","doi-asserted-by":"crossref","first-page":"e562","DOI":"10.3324\/haematol.2018.213512","article-title":"ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients","volume":"104","author":"Sibon","year":"2019","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.annonc.2025.01.023_bib40","doi-asserted-by":"crossref","first-page":"e671","DOI":"10.1016\/S2352-3026(24)00171-6","article-title":"Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study","volume":"11","author":"Herrera","year":"2024","journal-title":"Lancet Haematol"},{"issue":"19","key":"10.1016\/j.annonc.2025.01.023_bib41","doi-asserted-by":"crossref","first-page":"5550","DOI":"10.1182\/bloodadvances.2020003971","article-title":"Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2","volume":"6","author":"Savage","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.annonc.2025.01.023_bib42","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/bjh.17194","article-title":"UK guidelines on the diagnosis and treatment of breast implant-associated anaplastic large cell lymphoma on behalf of the medicines and healthcare products regulatory agency plastic, reconstructive and aesthetic surgery expert advisory group","volume":"192","author":"Turton","year":"2021","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.annonc.2025.01.023_bib43","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1200\/JCO.2015.63.3412","article-title":"Complete surgical excision is essential for the management of patients with breast implant-associated anaplastic large-cell lymphoma","volume":"34","author":"Clemens","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2025.01.023_bib44","doi-asserted-by":"crossref","first-page":"331","DOI":"10.4174\/astr.2017.93.6.331","article-title":"Extensive silicone lymphadenopathy after breast implant insertion mimicking malignant lymphadenopathy","volume":"93","author":"Lee","year":"2017","journal-title":"Ann Surg Treat Res"},{"issue":"6","key":"10.1016\/j.annonc.2025.01.023_bib45","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.clbc.2013.08.009","article-title":"Implant-associated primary anaplastic large-cell lymphoma with simultaneous involvement of bilateral breast capsules","volume":"13","author":"Bautista-Quach","year":"2013","journal-title":"Clin Breast Cancer"},{"issue":"2","key":"10.1016\/j.annonc.2025.01.023_bib46","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1200\/JCO.2013.52.7911","article-title":"Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients","volume":"32","author":"Miranda","year":"2014","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.annonc.2025.01.023_bib47","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.clml.2019.10.007","article-title":"Intensive induction therapy compared with CHOP for hepatosplenic T-cell lymphoma","volume":"20","author":"Klebaner","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"32","key":"10.1016\/j.annonc.2025.01.023_bib48","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.1200\/JCO.2009.22.6688","article-title":"Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms","volume":"27","author":"Ravandi","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2025.01.023_bib49","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/leu.2014.280","article-title":"Allogeneic and autologous stem cell transplantation for hepatosplenic T-cell lymphoma: a retrospective study of the EBMT Lymphoma Working Party","volume":"29","author":"Tanase","year":"2015","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.annonc.2025.01.023_bib50","first-page":"137","article-title":"(18)F-FDG PET\/CT findings in hepatosplenic Gamma-Delta T-cell lymphoma: case reports and review of the literature","volume":"8","author":"Cho","year":"2018","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"11","key":"10.1016\/j.annonc.2025.01.023_bib51","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S1470-2045(09)70265-7","article-title":"Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009","volume":"10","author":"Kwong","year":"2009","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2025.01.023_bib52","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ijrobp.2007.05.073","article-title":"Early or up-front radiotherapy improved survival of localized extranodal NK\/T-cell lymphoma, nasal-type in the upper aerodigestive tract","volume":"70","author":"Huang","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"32","key":"10.1016\/j.annonc.2025.01.023_bib53","doi-asserted-by":"crossref","first-page":"4044","DOI":"10.1200\/JCO.2012.45.6541","article-title":"Concurrent chemoradiotherapy for localized nasal natural killer\/T-cell lymphoma: an updated analysis of the Japan clinical oncology group study JCOG0211","volume":"30","author":"Yamaguchi","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2025.01.023_bib54","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/annonc\/mdx684","article-title":"Sequential chemotherapy\/radiotherapy was comparable with concurrent chemoradiotherapy for stage I\/II NK\/T-cell lymphoma","volume":"29","author":"Kwong","year":"2018","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2025.01.023_bib55","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.ijrobp.2013.08.040","article-title":"High-dose and extended-field intensity modulated radiation therapy for early-stage NK\/T-cell lymphoma of Waldeyer's ring: dosimetric analysis and clinical outcome","volume":"87","author":"Bi","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.annonc.2025.01.023_bib56","doi-asserted-by":"crossref","first-page":"6605","DOI":"10.2147\/OTT.S155930","article-title":"Asparagine synthetase expression is associated with the sensitivity to asparaginase in extranodal natural killer\/T-cell lymphoma in vivo and in vitro","volume":"11","author":"Liu","year":"2018","journal-title":"Onco Targets Ther"},{"issue":"15","key":"10.1016\/j.annonc.2025.01.023_bib57","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1182\/blood-2012-05-431460","article-title":"SMILE for natural killer\/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group","volume":"120","author":"Kwong","year":"2012","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.annonc.2025.01.023_bib58","doi-asserted-by":"crossref","first-page":"5223","DOI":"10.1158\/1078-0432.CCR-16-0153","article-title":"DDGP versus SMILE in newly diagnosed advanced natural killer\/T-cell lymphoma: a randomized controlled, multicenter, open-label study in China","volume":"22","author":"Li","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.annonc.2025.01.023_bib59","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2010-09-307454","article-title":"Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK\/T-cell lymphoma, a phase 2 study","volume":"117","author":"Jaccard","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.annonc.2025.01.023_bib60","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1080\/10245332.2016.1264163","article-title":"Effectiveness of pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) chemotherapy combined with radiotherapy in newly diagnosed, stage IE to IIE, nasal-type, extranodal natural killer\/T-cell lymphoma","volume":"22","author":"Wei","year":"2017","journal-title":"Hematology"},{"issue":"5","key":"10.1016\/j.annonc.2025.01.023_bib61","doi-asserted-by":"crossref","first-page":"e336","DOI":"10.1016\/S2352-3026(24)00066-8","article-title":"First-line sintilimab with pegaspargase, gemcitabine, and oxaliplatin in advanced extranodal natural killer\/T cell lymphoma (SPIRIT): a multicentre, single-arm, phase 2 trial","volume":"11","author":"Tian","year":"2024","journal-title":"Lancet Haematol"},{"issue":"12","key":"10.1016\/j.annonc.2025.01.023_bib62","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.3109\/10428194.2015.1037764","article-title":"High-dose therapy and autologous stem cell transplantation for extra-nodal NK\/T lymphoma in patients from the Western hemisphere: a study from the European Society for Blood and Marrow Transplantation","volume":"56","author":"Fox","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.annonc.2025.01.023_bib63","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/bjh.14879","article-title":"Allogeneic haematopoietic cell transplantation for extranodal natural killer\/T-cell lymphoma, nasal type: a CIBMTR analysis","volume":"182","author":"Kanate","year":"2018","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.annonc.2025.01.023_bib64","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1002\/ajh.26200","article-title":"Outcome after hematopoietic stem cell transplantation in patients with extranodal natural killer\/T-Cell lymphoma, nasal type: a French study from the Soci\u00e9t\u00e9 Francophone de Greffe de Moelle et de Th\u00e9rapie Cellulaire (SFGM-TC)","volume":"96","author":"Philippe Walter","year":"2021","journal-title":"Am J Hematol"},{"issue":"18","key":"10.1016\/j.annonc.2025.01.023_bib65","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2009-07-231324","article-title":"Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation","volume":"115","author":"Sieniawski","year":"2010","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.annonc.2025.01.023_bib66","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1182\/blood-2021-153709","volume":"138","author":"Sibon","year":"2021","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.annonc.2025.01.023_bib67","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1182\/blood.2019000402","article-title":"Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia","volume":"134","author":"Staber","year":"2019","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.annonc.2025.01.023_bib68","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1182\/blood.V98.6.1721","article-title":"High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H","volume":"98","author":"Dearden","year":"2001","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.annonc.2025.01.023_bib69","doi-asserted-by":"crossref","first-page":"5799","DOI":"10.1182\/blood-2011-08-372854","article-title":"Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route","volume":"118","author":"Dearden","year":"2011","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.annonc.2025.01.023_bib70","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S0002-9343(00)00406-X","article-title":"Low-dose methotrexate for the treatment of patients with large granular lymphocyte leukemia associated with rheumatoid arthritis","volume":"108","author":"Hamidou","year":"2000","journal-title":"Am J Med"},{"issue":"5","key":"10.1016\/j.annonc.2025.01.023_bib71","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/leu.2013.359","article-title":"Cyclophosphamide as a first-line therapy in LGL leukemia","volume":"28","author":"Moignet","year":"2014","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.annonc.2025.01.023_bib72","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3109\/10428190903470851","article-title":"Long-term safety and efficacy of cyclosporin A therapy for T-cell large granular lymphocyte leukemia","volume":"51","author":"Pawarode","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"16","key":"10.1016\/j.annonc.2025.01.023_bib73","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.annonc.2025.01.023_bib74","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2017-05-780049","article-title":"Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma","volume":"130","author":"Pro","year":"2017","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.annonc.2025.01.023_bib75","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.1182\/bloodadvances.2023012531","article-title":"Treatment strategies and outcome in relapsed peripheral T-cell lymphoma: results from the Netherlands Cancer Registry","volume":"8","author":"Brink","year":"2024","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.annonc.2025.01.023_bib76","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.annonc.2025.01.023_bib77","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study","volume":"33","author":"O'Connor","year":"2015","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2025.01.023_bib78","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O'Connor","year":"2011","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2025.01.023_bib79","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","article-title":"Activity of the PI3K-\u03b4,\u03b3 inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma","volume":"131","author":"Horwitz","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.annonc.2025.01.023_bib80","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1200\/JCO.2012.43.7285","article-title":"Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial","volume":"31","author":"Damaj","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2025.01.023_bib81","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1080\/10428190601137658","article-title":"Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine","volume":"48","author":"Advani","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"13","key":"10.1016\/j.annonc.2025.01.023_bib82","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1016\/j.ejca.2013.04.029","article-title":"A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial","volume":"49","author":"Morschhauser","year":"2013","journal-title":"Eur J Cancer"},{"issue":"21","key":"10.1016\/j.annonc.2025.01.023_bib83","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1182\/blood-2018-04-840538","article-title":"Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma","volume":"132","author":"Lemonnier","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.annonc.2025.01.023_bib84","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1016\/S2352-3026(24)00102-9","article-title":"Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study","volume":"11","author":"Dupuis","year":"2024","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.annonc.2025.01.023_bib85","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13045-020-00892-4","article-title":"Allogeneic stem cell transplantation for peripheral T cell lymphomas: a retrospective study in 285 patients from the Soci\u00e9t\u00e9 Francophone de Greffe de Moelle et de Th\u00e9rapie Cellulaire (SFGM-TC)","volume":"13","author":"Mamez","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2025.01.023_bib86","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/bjh.18052","article-title":"Impact of conditioning regimen intensity on the outcomes of peripheral T-cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T-cell lymphoma patients undergoing allogeneic transplant","volume":"197","author":"Savani","year":"2022","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.annonc.2025.01.023_bib87","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1182\/bloodadvances.2021005899","article-title":"Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics","volume":"6","author":"Hamadani","year":"2022","journal-title":"Blood Adv"},{"issue":"20","key":"10.1016\/j.annonc.2025.01.023_bib88","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2025.01.023_bib89","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1756-8722-7-24","article-title":"Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies","volume":"7","author":"Bartlett","year":"2014","journal-title":"J Hematol Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2025.01.023_bib90","doi-asserted-by":"crossref","first-page":"E319","DOI":"10.1002\/ajh.25967","article-title":"Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma relapsed\/refractory to chemotherapy","volume":"95","author":"Bossi","year":"2020","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.annonc.2025.01.023_bib91","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1111\/cas.14671","article-title":"Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: an open-label phase II trial","volume":"111","author":"Fukano","year":"2020","journal-title":"Cancer Sci"},{"issue":"12","key":"10.1016\/j.annonc.2025.01.023_bib92","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/S1470-2045(21)00536-2","article-title":"Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study","volume":"22","author":"Fischer","year":"2021","journal-title":"Lancet Oncol"},{"issue":"34","key":"10.1016\/j.annonc.2025.01.023_bib93","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1200\/JCO.20.00157","article-title":"Stem cell transplantation and vinblastine monotherapy for relapsed pediatric anaplastic large cell lymphoma: results of the international, prospective ALCL-relapse trial","volume":"38","author":"Kn\u00f6rr","year":"2020","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.annonc.2025.01.023_bib94","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","article-title":"PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase","volume":"129","author":"Kwong","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.annonc.2025.01.023_bib95","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00277-017-3127-2","article-title":"PD1 blockade with low-dose nivolumab in NK\/T cell lymphoma failing L-asparaginase: efficacy and safety","volume":"97","author":"Chan","year":"2018","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.annonc.2025.01.023_bib96","doi-asserted-by":"crossref","first-page":"254","DOI":"10.5045\/br.2015.50.4.254","article-title":"Complete remission in CD30-positive refractory extranodal NK\/T-cell lymphoma with brentuximab vedotin","volume":"50","author":"Kim","year":"2015","journal-title":"Blood Res"},{"issue":"1","key":"10.1016\/j.annonc.2025.01.023_bib97","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1016\/S2352-3026(15)00227-6","article-title":"Alemtuzumab in T-cell large granular lymphocytic leukaemia: interim results from a single-arm, open-label, phase 2 study","volume":"3","author":"Dumitriu","year":"2016","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1016\/j.annonc.2025.01.023_bib98","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/bjh.19476","article-title":"Efficacy of ruxolitinib in the treatment of relapsed\/refractory large granular lymphocytic leukaemia","volume":"205","author":"Marchand","year":"2024","journal-title":"Br J Haematol"},{"issue":"26","key":"10.1016\/j.annonc.2025.01.023_bib99","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood.2021013379","article-title":"A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK\/STAT targeting in T-cell lymphomas","volume":"138","author":"Moskowitz","year":"2021","journal-title":"Blood"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425000596?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425000596?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T01:39:48Z","timestamp":1780277988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753425000596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":99,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0923753425000596"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2025.01.023","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peripheral T- and natural killer-cell lymphomas: ESMO\u2013EHA Clinical Practice Guideline for diagnosis, treatment and follow-up","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2025.01.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by John Wiley & Sons on behalf of European Hematology Association and by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}